BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 32500478)

  • 41. Large-scale SAR analysis.
    Bajorath J
    Drug Discov Today Technol; 2013 Sep; 10(3):e419-26. PubMed ID: 24050139
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prediction methods and databases within chemoinformatics: emphasis on drugs and drug candidates.
    Jónsdóttir SO; Jørgensen FS; Brunak S
    Bioinformatics; 2005 May; 21(10):2145-60. PubMed ID: 15713739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activity landscape of DNA methyltransferase inhibitors bridges chemoinformatics with epigenetic drug discovery.
    Naveja JJ; Medina-Franco JL
    Expert Opin Drug Discov; 2015 Oct; 10(10):1059-70. PubMed ID: 26289576
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advances in Activity Cliff Research.
    Dimova D; Bajorath J
    Mol Inform; 2016 May; 35(5):181-91. PubMed ID: 27492084
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ACGCN: Graph Convolutional Networks for Activity Cliff Prediction between Matched Molecular Pairs.
    Park J; Sung G; Lee S; Kang S; Park C
    J Chem Inf Model; 2022 May; 62(10):2341-2351. PubMed ID: 35522160
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Simplified activity cliff network representations with high interpretability and immediate access to SAR information.
    Hu H; Bajorath J
    J Comput Aided Mol Des; 2020 Sep; 34(9):943-952. PubMed ID: 32500478
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activity cliff networks for medicinal chemistry.
    Stumpfe D; Bajorath J
    Drug Dev Res; 2014 Aug; 75(5):291-8. PubMed ID: 25160069
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evolving Concept of Activity Cliffs.
    Stumpfe D; Hu H; Bajorath J
    ACS Omega; 2019 Sep; 4(11):14360-14368. PubMed ID: 31528788
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Data structures and computational tools for the extraction of SAR information from large compound sets.
    Wawer M; Lounkine E; Wassermann AM; Bajorath J
    Drug Discov Today; 2010 Aug; 15(15-16):630-9. PubMed ID: 20547243
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modeling of activity landscapes for drug discovery.
    Bajorath J
    Expert Opin Drug Discov; 2012 Jun; 7(6):463-73. PubMed ID: 22475223
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systematic computational analysis of structure-activity relationships: concepts, challenges and recent advances.
    Peltason L; Bajorath J
    Future Med Chem; 2009 Jun; 1(3):451-66. PubMed ID: 21426126
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.